Nick A. Deeter, formerly of OrthoPediatrics Corp., has been named as the next Chief Executive Officer and Chairman of the Board at Nextremity Solutions, Inc. Deeter has more than 30 years of business leadership and health care industry experience.
Nick Deeter New CEO, Chairman at Nextremity
2 min read Premium comments
After initiating his orthopedic career at Zimmer, Deeter spent seven years with DePuy Orthopaedics (a Johnson & Johnson company) where he was responsible for health care compliance administration, medical affairs, and Orthogenesis (custom devices). Then in 2006 Deeter founded OrthoPediatrics, Corp., the only orthopedic company focused on implants for children.
“I am excited to lead Nextremity Solutions through its next growth phase. The foot and ankle segment of the orthopaedic industry continues to grow rapidly. The intellectual property behind the company’s products is second to none, ” said Deeter in the January 14, 2015 news release.
Rod K. Mayer will continue as president of Nextremity where he will focus on product development, sales and marketing, as well as devoting himself to building and maintaining surgeon relationships.
Mayer noted, “Having known Nick since our high school years of being teammates on the football field, I am positive that our combined skillsets and passion for excellence will bring strength and an overall commitment to executing on our strategy of becoming recognized as the leader for innovative product development in the minds of surgeons in the global foot and ankle market. I look forward to a very exciting and productive 2015 and to a successful journey as we continue to build our business together, one relationship at a time.”
“Rod and I have been friends since we were teenagers, growing up in Warsaw. As successful entrepreneurs, in the Orthopaedic Capital of the World, we were destined to eventually co-labor together, to help our local community during uncertain times and advance the care of individuals, worldwide, with foot and ankle problems, ” says Deeter.
Deeter told OTW, “We have some very innovative products that are about to be launched to the worldwide foot and ankle orthopaedic market. I will focus on the international sales effort and our president, Rod Mayer, will focus on domestic sales. We will quickly gain the mindshare of surgeons that perform foot and ankle surgery as being the company that provides solutions and better surgical outcomes through innovation.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.